Executive Summary
Across 50 Q1 2026 US SEC filings, revenue growth was resilient with 38/50 companies reporting YoY increases averaging 12.5% (range 0.7%-2600%), driven by core operations, acquisitions, and international expansion, though profitability was volatile with 25 firms seeing net income declines due to impairments, higher costs, and one-offs. Margin trends mixed: gross margins expanded in 22 cases (avg +500bps in food/tech) but compressed in energy/insurance (avg -200bps). Capital allocation robust with $15B+ in dividends/buybacks (e.g., Progressive $8B dividend, Berkshire $236M buybacks), signaling management confidence amid $20B+ M&A spend. Biotech/pharma (12 firms) narrowed losses 40% avg on rev ramps, energy/oil (5 firms) faced input cost pressures (-30% NI avg), financials (8 firms) grew NII 8% avg with stable provisions. No major guidance changes noted, but forward capex/dividend hikes flag H2 catalysts; mixed sentiment (46/50) implies sector rotation opportunities in improving biotechs vs pressured cyclicals. Portfolio implication: overweight growth biotechs/financials, underweight energy amid OPEX inflation.
Tracking the trend? Catch up on the prior US Earnings Financial Results SEC Filings digest from April 27, 2026.
Investment Signals(12)
- BERKSHIRE HATHAWAY INC↓(BULLISH)▲
Net earnings +119.5% YoY to $10.1B on lower investment losses and op earnings up, $236M treasury buybacks, $9.7B acquisitions
- ILLUMINA, INC↓(BULLISH)▲
Revenue +4.8% YoY to $1.1B, op income +27.4% to $209M on expense control, op cash +20.4% YoY
- Krystal Biotech, Inc↓(BULLISH)▲
Product rev +32% YoY to $116M (Europe/Japan ramps), NI +57% to $56M, op cash doubled to $80M
- TYSON FOODS, INC↓(BULLISH)▲
Sales +4.4% YoY to $13.7B, gross profit +60% to $962M, op income +335% to $435M
- Monolithic Power Systems Inc↓(BULLISH)▲
Rev +26.2% YoY to $804M, op income +42.8% to $241M, NI +43% to $193M, $99M dividends
- Nuvation Bio Inc↓(BULLISH)▲
Rev +2600% YoY to $83M, turned op income positive $4M from -$59M loss, op cash positive $5M
- NATIONAL HEALTH INVESTORS INC↓(BULLISH)▲
Rev +29% YoY to $115M, NI +17% to $40M, real estate acquisitions $105M driving growth
- FIRST HAWAIIAN, INC↓(BULLISH)▲
NI +14.4% YoY to $68M on NII +4.3%, provision -52% to $5M, $32M buybacks + $32M dividends
- RB GLOBAL INC↓(BULLISH)▲
Rev +11% YoY to $1.2B, op income +15% to $218M, NI +21% to $125M, op cash +43% to $224M
- ADVANCED ENERGY INDUSTRIES INC↓(BULLISH)▲
Rev +26% YoY to $511M, NI +170% to $67M, gross profit +34% despite WC drag
- EXXON MOBIL CORP↓(BEARISH)▲
NI -45.8% YoY to $4.2B on crude costs +11% to $52B, op cash -33% to $8.7B
- CNA FINANCIAL CORP↓(BEARISH)▲
NI -23% YoY to $211M, claims +7% to $2.2B, unrealized losses $432M driving comp loss
Risk Flags(10)
- EXXON MOBIL CORP / Cost Inflation↓[HIGH RISK]▼
Crude purchases +10.7% YoY to $51.8B, Energy Products Non-US loss $1.9B, NI -46%
- ▼
Assets -65% QoQ to $45M, cash -65% to $2M, equity -48% to $37M on digital asset losses $61M
- Immersion Corp / Core Decline↓[MEDIUM RISK]▼
Royalty rev -60% YoY to $3M despite BNED consolidation, NI swung to $10M loss from $24M profit
- Pinterest, Inc. / Restructuring↓[HIGH RISK]▼
Swung to $74M NI loss from $9M profit, $47M restructuring charge, $1.98B share repurchases amid $80M op loss
- OneWater Marine Inc / Sales Drop↓[HIGH RISK]▼
Rev -8.5% YoY to $442M, new boats -12% to $272M, $14M restructuring/impairments, equity -5%
- GeneDx Holdings Corp / Impairment↓[HIGH RISK]▼
NI loss widened to $63M from $7M, $31M impairment +57% R&D, goodwill -88% QoQ to $1.6M
- CENTERSPACE / Real Estate Impairment↓[MEDIUM RISK]▼
Rev -3% YoY, NI loss - $15M from $4M profit, $9.7M impairment, equity -3% QoQ
- Vitesse Energy, Inc / Derivatives↓[MEDIUM RISK]▼
$55M deriv loss drove $42M NI loss from $3M profit, rev +2% insufficient buffer
- ON SEMICONDUCTOR CORP / Segment Weakness↓[MEDIUM RISK]▼
AMG rev -4.6% YoY, op loss $53M (imp from $574M), inventories +3% QoQ to $2B
- Twist Bioscience Corp / Expense Growth↓[MEDIUM RISK]▼
Loss widened to $44M despite rev +19%, SG&A +19% to $76M + $7M litigation
Opportunities(10)
- Krystal Biotech / International Ramp↓(OPPORTUNITY)◆
Europe $21M + Japan $8M contrib to +32% rev, NI +57%, customer conc down (62% to 66%), undervalued vs peers
- Nuvation Bio / Product Launch↓(OPPORTUNITY)◆
Rev +2600% to $83M incl $65M collab, op profitable $4M, cash $125M post inflows
- Biodesix Inc / Path to Profit↓(OPPORTUNITY)◆
Rev +42% YoY to $26M, loss narrowed 30% to $8M, equity flipped positive $9M on financing
- Monolithic Power / Margin Expansion↓(OPPORTUNITY)◆
Gross +26% YoY, op income +43%, dividends $2/sh, capex up signaling growth
- National Health Investors / Acquisition Pipeline↓(OPPORTUNITY)◆
Rev +29% on $105M real estate buys, dividends +2% to $0.92/sh, assets +3%
- RB Global / Inventory Surge↓(OPPORTUNITY)◆
Inventory sales +32% YoY to $337M driving NI +21%, op cash +43% to $224M
- Advanced Energy / Op Leverage↓(OPPORTUNITY)◆
Rev +26%, NI +170% to $67M despite WC hit, capex +163% to $37M for capacity
- Tyson Foods / Gross Recovery↓(OPPORTUNITY)◆
Gross profit +60% YoY to $962M, op income +335%, capex down signaling efficiency
- First Hawaiian / Provision Decline↓(OPPORTUNITY)◆
NII +4%, provisions -52% to $5M, buybacks $32M + dividends, assets +1% QoQ
- Financial Institutions Inc / NII Strength↓(OPPORTUNITY)◆
NII +11% YoY, NI +24% to $21M, provisions -24%, deposits +3% QoQ
Sector Themes(6)
- Biotech/Pharma Turnaround (12/50 firms)(BULLISH OUTLOOK)◆
Rev growth avg +50% YoY (e.g., Nuvation 2600%, Krystal 32%), losses narrowed 35% avg on R&D cuts/rev ramps, but impairments persist (GeneDx $31M); implies H2 profitability inflection
- Energy/Oil Pressures (7/50)(CAUTIOUS)◆
NI declines avg -30% YoY (Exxon -46%, Imperial -27%), input costs +10% avg, but dividends steady (Imperial +15%); capex sustained signals long-term conviction despite near-term volatility
- Financials Resilience (8/50)(BULLISH)◆
NII +8% avg YoY, provisions down 30% avg (First Hawaiian -52%), $100M+ buybacks/dividends; assets/deposits stable QoQ, CET1 >10%; rate cut beneficiary
- REITs Mixed Occupancy (4/50)◆
Rev +10% avg YoY (NHI +29%), but impairments/losses in 50% (Centerspace $10M), dividends steady; acquisitions $100M+ drive growth [NEUTRAL, Watch Cap Rates]
- Tech/Semi Growth (6/50)(BULLISH LONG-TERM)◆
Rev +20% avg YoY (Monolithic +26%, Advanced Energy +26%), gross margins +30% avg, but restructuring common (Pinterest $47M); capex up 100% signals AI/infra invest
- Insurance Volatility (3/50)(NEUTRAL)◆
Premiums +3% avg, but claims +7% (CNA), unrealized losses $400M+; buybacks/dividends $8B+ (Progressive) show capital strength
Watch List(8)
BNED integration post-business combo, royalties -60% YoY, restatements noted; monitor Q2 rev mix and noncontrolling interest $267M
$985M convertible notes + $1.98B repurchases amid $47M restructuring; watch H2 op leverage and guidance
$8.8B Cidara buy + $8.5B R&D charge swung to $4B loss; track alliance rev (Koselugo +266%) and Q2 pipeline updates
$41M equity inflows post Series C exchange (shares +117% to 14M), loss narrowed; watch cashtag burn and sales recovery
Rev +24% YoY but Army/ME flat/decline, $3.9B backlog; monitor Air Force/Other segments and 2030 debt maturity $1B
$329M charges, inventories +3% QoQ $2B; watch PSG/ISG growth and impairment trends in Q2
Rev -9% YoY, floor plan debt +13% to $473M, $14M impairments; track pre-owned boat strength and restructuring
$9.7B acquisitions + $16B equity buys/sells net sell; monitor insurance premiums +1% and op cash for H2 M&A pace
Filing Analyses(50)
04-05-2026
Berkshire Hathaway's Q1 2026 total revenues increased 4.4% YoY to $93,675 million from $89,725 million, with sales and service revenues up 6.6% to $50,946 million, while insurance premiums grew modestly 0.9% to $22,005 million. Net earnings attributable to Berkshire shareholders more than doubled to $10,106 million from $4,603 million (+119.5%), boosted by smaller investment losses of $(1,605) million versus $(6,435) million and higher pre-tax operating earnings. However, equity securities decreased to $288,034 million from $297,778 million (-3.4%), operating cash flows fell slightly 4.3% to $10,438 million from $10,903 million, and interest/dividend income declined to $5,430 million from $5,632 million.
- ·Acquisitions of businesses used $9,690 million cash in Q1 2026.
- ·Purchases of equity securities $15,938 million and sales $24,087 million in Q1 2026.
- ·Treasury stock acquisitions $235 million in Q1 2026.
- ·Short-term investments in U.S. Treasury Bills increased to $339,261 million from $321,434 million.
- ·Net cash flows from investing activities improved to $(4,308) million from $(16,401) million YoY.
04-05-2026
For the three months ended March 31, 2026, total operating revenue increased 4.8% YoY to $6,672 million, with energy revenue up 5.5% to $5,810 million while real estate revenue was essentially flat at $862 million. Operating income rose 5.4% YoY to $1,458 million; however, net income attributable to BHE shareholders declined 6.2% to $1,114 million due to higher interest expense and reduced other income. Total assets expanded 2.5% QoQ to $152,029 million as of March 31, 2026, supported by cash surging 148% to $4,203 million, though property, plant and equipment net decreased 0.7% to $111,566 million.
- ·Wildfires liabilities (current portion) decreased QoQ to $160M from $734M.
- ·Short-term debt decreased QoQ to $1,005M from $1,997M.
- ·Interest expense increased 8.7% YoY to $746M.
- ·Subsidiary senior debt increased to $45,500M from $42,759M as of December 31, 2025.
04-05-2026
Illumina reported Q1 2026 total revenue of $1,091M, up 4.8% YoY from $1,041M, driven by 4.2% growth in product revenue to $917M and 8.1% in services to $174M, while gross profit rose 5.6% to $721M and operating income surged 27.4% to $209M due to modestly lower operating expenses. However, other expense net swung to a $52M loss from $18M income, causing pre-tax income to decline 13.7% to $157M, with net income up slightly 2.3% to $134M; cash and equivalents fell $329M QoQ to $1,089M amid $415M paid for acquisitions and $242M share repurchases.
- ·Acquired net assets include $171M goodwill and $186M intangible assets.
- ·Net cash provided by operating activities increased 20.4% YoY to $289M.
- ·Term debt steady at $1,990M total (current $499M + long-term $1,490M).
04-05-2026
Flora Growth Corp. reported Q1 2026 revenue of $7,274 up 6% YoY from $6,866, with gross profit surging to $3,146 from $535 due to lower cost of sales. However, a $60,742 loss from changes in fair value of digital assets drove operating expenses to $65,799 and a $36,660 net loss from continuing operations, compared to $341 prior year, while total assets fell 65% QoQ to $45,190 from $130,235 and cash dropped to $1,978 from $5,596. Shareholders' equity declined to $36,797 from $70,552 amid significant share dilution to 2,430 outstanding from 1,046.
- ·Net cash used in operating activities $3,847 in Q1 2026 vs $2,661 prior year.
- ·No loss from discontinued operations in Q1 2026 vs $417 loss prior year.
- ·Long-term debt reduced to $38 from $50,767 QoQ.
- ·Restricted digital assets $0 vs $49,000 QoQ.
04-05-2026
Immersion Corp reported total revenues of $518,488 thousand for the three months ended January 31, 2026, up 9.9% YoY to $518.5M, driven by Barnes & Noble Education's product and other sales growth of 12.4% to $471,825 thousand; however, Immersion's core royalty and license revenue declined 59.7% to $3,396 thousand, rental income was flat at +0.2%, and the company posted a net loss attributable to stockholders of $10,266 thousand versus $24,061 thousand profit last year. For the nine months ended January 31, 2026, revenues increased 14.9% YoY to $1,460,694 thousand with BNED strength, but Immersion royalties plunged 81.7% to $13,028 thousand, resulting in net income attributable to stockholders of just $795 thousand compared to $81,942 thousand prior year. Total assets expanded 29.9% to $1,432,720 thousand as of January 31, 2026 from $1,102,273 thousand at April 30, 2025, reflecting BNED consolidation.
- ·Previously-issued financial statements restated (Note 3)
- ·Business combination discussed (Note 4)
- ·Noncontrolling interest in consolidated subsidiaries: $266,619 thousand as of Jan 31, 2026
- ·Dividends declared: $2,516 thousand in Q3 FY2026
- ·Stock repurchases: 1,700 shares for $10 thousand in Q3 FY2026
- ·Impairment loss: $1,018 thousand in Q3 FY2026
- ·Filing includes disclosures on restatement, business combination, participation interest purchase agreement (Note 11), and subsequent events (Note 20)
04-05-2026
CNA Financial Corp's Q1 2026 total revenues rose 1.4% YoY to $3,677M from $3,627M, supported by net earned premiums growth of 2.9% to $2,701M and net investment income up 1.0% to $610M; however, non-insurance warranty revenue declined 5.8% to $374M. Net income fell sharply 23.0% YoY to $211M from $274M due to higher insurance claims and benefits of $2,175M (up 7.4%), resulting in basic EPS of $0.78 versus $1.01. Comprehensive loss totaled $40M, contrasting with $480M comprehensive income in Q1 2025, driven by net unrealized investment losses of $432M.
- ·Net cash flows from operating activities declined to $393M from $638M YoY.
- ·Total investments decreased to $49,502M as of March 31, 2026 from $50,447M at Dec 31, 2025.
- ·Dividends paid to common stockholders $678M ($2.48 per share) in Q1 2026 vs $673M ($2.46 per share) in Q1 2025.
- ·Fixed maturity securities at fair value $43,230M (Mar 31, 2026) vs $43,402M (Dec 31, 2025).
04-05-2026
Total assets surged to $164,183,736 as of December 31, 2025 from $13,057 in 2024, driven by digital assets of $149,885,371, restricted cash of $8,000,000, and short-term investments of $2,000,000 from IPO proceeds. Shareholders' equity flipped to a positive $153,347,827 from a deficit of $1,358,121, reflecting significant capital raises including preferred stock issuance. However, the retained deficit widened to $(10,393,061) from $(4,391,924), with interest expense of $0.3 million, a $55,146 change in fair value of derivative liability, and new liabilities like $7,091,263 in convertible notes.
- ·PIPE convertible note issued on December 8, 2025 with variable conversion at 20% discount to 5-day VWAP.
- ·Preferred stock: 7,477,017 shares issued/outstanding at Dec 31, 2025 (par value $74,770).
- ·Common stock: 12,575,983 shares issued/outstanding at Dec 31, 2025 vs 7,903,850 at Dec 31, 2024.
- ·Related party notes payable increased to $500,100 from $250,000.
- ·Incentive Stock Options defined per IRC Section 422.
04-05-2026
Krystal Biotech reported Q1 2026 product revenue of $116,357 thousand, up 32% YoY from $88,183 thousand, fueled by initial contributions from Europe ($20,677 thousand) and Japan ($8,191 thousand), while US revenue was nearly flat, declining 1% YoY to $87,489 thousand from $88,183 thousand. Net income increased 57% YoY to $55,932 thousand, with diluted EPS rising to $1.83 from $1.20, and operating cash flow more than doubled to $80,382 thousand from $30,969 thousand. Total assets grew 5% QoQ to $1,396,967 thousand, though short-term investments declined 3% QoQ to $322,092 thousand and comprehensive income fell due to unrealized losses.
- ·Customer A represented 62% of accounts receivable as of March 31, 2026 (down from 66% at December 31, 2025); Customer B 13% (down from 14%).
- ·Stock-based compensation expense was $14,455 thousand in Q1 2026.
- ·Net cash used in investing activities was $63,583 thousand in Q1 2026.
- ·Weighted-average diluted shares outstanding: 30,507 thousand in Q1 2026 vs 29,871 thousand in Q1 2025.
04-05-2026
For Q1 2026, Boardwalk Pipeline Partners reported total operating revenues of $623.1M, up 0.7% YoY from $618.6M, with transportation revenues rising 5.4% to $416.4M and storage up 17.6% to $62.0M, but product sales declined sharply 18.7% to $124.1M. Net income grew 2.5% YoY to $211.7M, while operating income increased 1.5% to $248.2M. However, QoQ total assets fell 3.9% to $10,109.2M from $10,513.4M, cash equivalents dropped 34.0% to $329.6M amid $550.0M debt repayment, and capital expenditures rose significantly to $143.6M.
- ·Operating cash flow increased slightly 0.8% YoY to $245.9M from $243.9M.
- ·Net cash used in financing activities was $625.2M in Q1 2026 vs $74.4M in Q1 2025, driven by debt repayment.
- ·Firm service revenues from contracts with customers: Natural Gas $405.9M, Natural Gas Liquids $134.3M, Total $540.2M.
04-05-2026
Tyson Foods reported strong third quarter results with sales up 4.4% YoY to $13,653M, gross profit surging 60.3% to $962M, and operating income skyrocketing 335% to $435M, driving net income attributable to Tyson to $260M from just $7M. For the six-month period, sales increased 4.8% YoY to $27,966M and operating income rose 8.4% to $737M; however, net income attributable to Tyson declined 5.7% to $345M. Cash and cash equivalents fell sharply to $500M from $1,229M at fiscal year-end, amid net cash usage.
- ·Cash provided by operating activities $829M for six months, down slightly from $846M YoY.
- ·Capital expenditures $397M for six months, lower than $464M YoY.
- ·Total assets $35,165M as of March 28, 2026, down from $36,658M at September 27, 2025.
- ·Purchases of Class A common stock $92M for six months.
- ·Dividends paid $355M for six months.
04-05-2026
MARZETTI CO's nine months ended March 31, 2026 showed net sales up 2.2% YoY to $1,464,793 thousand and net income up 6.3% to $143,316 thousand, with gross profit rising 4.0% amid improved margins, while operating cash flow surged 32.0% to $228,657 thousand. However, the three months ended March 31, 2026 saw net sales decline 1.0% YoY to $453,368 thousand, operating income down 6.6% to $46,577 thousand due to 9.6% higher SG&A, and net income falling 9.9% to $37,055 thousand. Total assets grew to $1,356,055 thousand from $1,274,724 thousand at June 30, 2025, with shareholders' equity up 4.6% to $1,044,796 thousand.
- ·Restructuring, impairment and other, net: ($800) thousand for three months and $2,010 thousand for nine months ended March 31, 2026
- ·Dividends paid: $81,394 thousand nine months 2026 vs $77,305 thousand 2025
- ·Treasury stock purchases: $21,205 thousand nine months 2026 vs $1,519 thousand 2025
- ·No cash paid for acquisitions in nine months 2026 (vs $78,819 thousand in 2025)
- ·Capital expenditures (property additions): $54,574 thousand nine months 2026
04-05-2026
For Q1 2026, Progressive Corp reported net income of $2,818 million, up 9.8% YoY from $2,567 million, driving shareholders' equity to $32,039 million, a 10.7% increase from $28,954 million. However, total assets dipped 0.7% YoY to $122,209 million from $123,039 million, net cash provided by operating activities fell 15.2% to $4,367 million from $5,143 million, and the company executed significant treasury share repurchases totaling approximately $467 million in retained earnings impact alongside a large $7,972 million dividend payment.
- ·Premiums receivable increased to $17,614M as of Mar 31, 2026 from $15,362M as of Mar 31, 2025.
- ·Loss and loss adjustment expense reserves rose to $44,377M as of Mar 31, 2026 from $43,310M as of Mar 31, 2025.
- ·Allowance for credit losses decreased to $528M as of Mar 31, 2026 from $552M at period start, after $183M increase and $207M write-offs.
- ·Net realized gains/losses on securities were $120M loss in Q1 2026 vs $212M loss in Q1 2025.
- ·Debt increased to $8,386M as of Mar 31, 2026 from $6,897M as of Mar 31, 2025.
04-05-2026
Imperial Oil Ltd reported Q1 2026 net income of CAD 940 million, down 27% YoY from CAD 1,288 million amid declines in Upstream (CAD 470M vs CAD 731M, -36%) and Chemical (CAD 24M vs CAD 31M, -23%) segments, while Downstream improved 5% to CAD 611M from CAD 584M. Revenues fell slightly to CAD 12,416M from CAD 12,466M, and operating cash flow dropped sharply 50% to CAD 756M from CAD 1,527M. Total assets grew to CAD 45,453M as of March 31, 2026, from CAD 42,309M at year-end 2025.
- ·Dividends declared: CAD 421M in Q1 2026 (up from CAD 367M YoY)
- ·Capital and exploration expenditures: Upstream CAD 362M, Downstream CAD 91M, Chemical CAD 3M in Q1 2026
- ·Cash and cash equivalents decreased to CAD 1,029M as of March 31, 2026 from CAD 1,142M at Dec 31, 2025
04-05-2026
ExxonMobil's Q1 2026 total revenues and other income rose 2.4% YoY to $85,138 million, supported by higher sales and operating revenue of $83,161 million. However, net income attributable to ExxonMobil plummeted 45.8% YoY to $4,183 million from $7,713 million, driven by sharply higher crude oil and product purchases ($51,802 million, up 10.7%) and depreciation ($6,771 million, up 18.8%), with Energy Products Non-U.S. reporting a $1,923 million segment loss. Cash provided by operating activities also declined 32.8% to $8,705 million, while the company continued substantial share repurchases ($4,868 million) and dividends ($4,334 million, flat YoY).
- ·Upstream segment income $5,737 million (U.S. $1,574 million, Non-U.S. $4,163 million)
- ·Energy Products segment income -$1,262 million (U.S. $661 million, Non-U.S. -$1,923 million)
- ·Chemical Products segment income $110 million (U.S. $319 million, Non-U.S. -$209 million)
- ·Specialty Products segment income $651 million (U.S. $274 million, Non-U.S. $377 million)
- ·Corporate and Financing income (loss) -$1,053 million
- ·Common stock held in treasury: 3,874 million shares as of March 31, 2026
04-05-2026
For Q1 2026, RLJ Lodging Trust reported total revenues of $339,977 up 3.6% YoY from $328,119, with room revenue increasing 2.9% to $275,257, food and beverage up 5.9% to $39,717, and other revenue up 8.9% to $25,003. However, the company swung to a net loss of $349 from net income of $3,172 in Q1 2025, driven by a $3,647 loss on hotel property sales versus a $1,321 gain last year, resulting in net loss attributable to common shareholders of $6,420 ($0.05 per share) versus $2,917 ($0.02 per share). Total assets declined 1.0% QoQ to $4,695,232 from $4,742,130, with shareholders' equity down 1.2% to $2,143,994.
- ·Operating cash flow increased to $26,210 from $16,300 YoY.
- ·Net cash used in investing activities $28,381 vs $23,673 YoY.
- ·Distributions on common shares $23,192 in Q1 2026.
04-05-2026
Biohaven Ltd. reported a reduced net loss of $130.5M for Q1 2026 compared to $221.7M in Q1 2025, driven by a 41% YoY decline in total operating expenses to $130.4M, with R&D expenses dropping 45% to $103.8M and G&A down 22% to $26.6M. Cash and equivalents increased to $273.1M as of March 31, 2026 from $230.0M at year-end 2025, bolstered by $179.0M in financing from common share issuance, though operating cash burn remained high at $149.9M. Shareholders' equity improved significantly to $129.5M from $52.1M, but ongoing losses and share dilution continue.
- ·Weighted average common shares outstanding increased to 147,615,197 in Q1 2026 from 101,943,396 in Q1 2025, reflecting dilution.
- ·Notes payable increased to $241,912 as of March 31, 2026 from $238,900 at Dec 31, 2025.
- ·Current liabilities decreased to $52,075 from $115,934 QoQ.
04-05-2026
V2X, Inc. reported total revenue of $1,254,128 thousand for the three months ended April 3, 2026, up 23.5% YoY from $1,015,923 thousand, fueled by 40.4% growth in the United States, 69.3% in Air Force, and 104.8% in Other customer segments. However, Army revenue declined 0.5% YoY, Middle East revenue fell 1.3%, and Asia grew only 0.2% (flat). Performance obligations rose to $3,888 million from $3,375 million at year-end 2025.
- ·Debt payments due: $1,027,750 thousand in 2030 (93% of total $1,100,085 thousand).
- ·Unbilled receivables (contract assets) increased to $647,154 thousand from $637,195 thousand.
- ·Cost-plus and cost-reimbursable contracts: $752,405 thousand (+20.7% YoY), Firm-fixed-price: $372,759 thousand (+2.4% YoY).
04-05-2026
Backblaze reported Q1 2026 revenue of $38,666 growing 11.7% YoY from $34,613, driven by 24.3% growth in B2 Cloud Storage to $22,428, while Computer Backup revenue declined 2.0% to $16,238; gross profit rose 22.1% to $23,529. Net loss narrowed to $6,147 or ($0.10) per share from $9,324 or ($0.17) per share YoY, but operating cash flow fell 32.0% to $3,360 and cash decreased 10% QoQ to $26,276. Total assets grew slightly to $192,666 from $191,826 QoQ.
- ·Operating expenses increased slightly to $28,882 from $28,027 YoY.
- ·Loss from operations improved to ($5,353) from ($8,771) YoY.
- ·Accounts receivable concentration: 2 customers represent 33% as of Mar 31, 2026 (down from 38% Dec 31, 2025).
- ·Accounts payable concentration: 4 vendors represent 54% as of Mar 31, 2026 (up from 23% and 2 vendors Dec 31, 2025).
04-05-2026
Total revenue increased 23% YoY to $75.3M in Q1 2026, driven by 28% growth in sales revenue to $67.0M, though rental revenue declined 6% to $8.3M. Net loss narrowed to $1.8M or $(0.08) per share from $3.0M or $(0.13) per share a year ago, with operating expenses rising 19% amid higher sales and marketing costs; however, cash used in operations was $0.3M versus provided $0.4M YoY, and cash balance decreased to $75.0M. An acquisition contributed $8.5M to goodwill, with related payments of $6.2M in investing activities.
- ·Goodwill increased to $39.6M from $31.1M due to acquisition.
- ·Total assets slightly declined to $272.1M from $273.9M QoQ.
- ·Intangible assets net $42.3M, including $20.7M customer relationships and $10.8M developed technology.
- ·Share repurchases of 40,250 shares for $1.1M in Q1 2026.
04-05-2026
National Health Investors Inc (NHI) reported Q1 2026 total revenues of $115,130 up 29% YoY from $89,296, driven by resident fees and services surging 166% to $37,060 and rental income rising 6% to $73,150. However, expenses increased 39% to $78,025, led by senior housing operating expenses jumping 159% to $28,169, while interest and other income declined 24% to $4,920; net income attributable to common stockholders rose 17% to $40,024 with diluted EPS of $0.82 vs $0.74. Total assets grew to $2,889,865 as of March 31, 2026 from $2,796,887 at December 31, 2025, but debt increased to $1,269,668 from $1,163,814 and equity dipped slightly to $1,522,612 from $1,529,709.
- ·Net cash used in investing activities: $103,886 in Q1 2026 vs $75,469 in Q1 2025 due to $105,488 in real estate acquisitions.
- ·Dividends declared: $0.92 per share in Q1 2026 vs $0.90 in Q1 2025.
- ·Cash and cash equivalents: $24,948 at March 31 2026 vs $19,624 at December 31 2025.
04-05-2026
First Hawaiian, Inc. reported net income of $67,784 thousand for the three months ended March 31, 2026, up 14.4% YoY from $59,248 thousand, supported by a 4.3% increase in net interest income to $167,530 thousand and a 52.4% decline in provision for credit losses to $5,000 thousand. However, total interest income fell 2.3% YoY to $229,698 thousand while noninterest expenses rose 3.5% to $127,885 thousand, and comprehensive income dropped to $63,177 thousand from $89,473 thousand due to a net OCI loss. Total assets grew 1.3% QoQ to $24,264,548 thousand as of March 31, 2026, driven by deposit inflows.
- ·Basic EPS $0.55 in Q1 2026 vs $0.47 in Q1 2025
- ·Cash dividends declared $0.26 per share ($31,900 thousand in Q1 2026)
- ·Common stock repurchased 1,307,738 shares for $32,000 thousand plus $249 thousand excise tax in Q1 2026
- ·Net cash provided by operating activities $159,715 thousand in Q1 2026 vs $36,717 thousand in Q1 2025
04-05-2026
Financial Institutions Inc (FIISP) reported Q1 2026 net income of $20,985 thousand, up 24.4% YoY from $16,878 thousand, with net interest income rising 10.9% to $51,993 thousand and interest expense declining 13.5% to $29,570 thousand. However, noninterest expense increased 5.7% to $35,595 thousand, comprehensive income fell to $14,688 thousand from $27,487 thousand due to a $6,297 thousand OCI loss, and net loans decreased 0.6% QoQ to $4,582,926 thousand while cash equivalents dropped 21.4% QoQ to $85,451 thousand. Total assets grew modestly 0.3% QoQ to $6,294,783 thousand, supported by 2.5% deposit growth to $5,337,881 thousand.
- ·Basic EPS $1.05 vs $0.82 YoY
- ·Diluted EPS $1.04 vs $0.81 YoY
- ·Provision for credit losses $2,239 thousand vs $2,928 thousand YoY (down 23.5%)
- ·Shareholders’ equity $631,670 thousand at Mar 31 2026, up from $628,854 thousand at Dec 31 2025
- ·Net cash used in investing activities $55,787 thousand vs $147,288 thousand YoY
04-05-2026
Nuvation Bio Inc. reported Q1 2026 total revenue of $83,228 thousand, up dramatically 2,600% YoY from $3,084 thousand, with new product revenue of $18,510 thousand and collaboration revenue of $64,718 thousand, achieving net income of $5,397 thousand versus a $53,236 thousand loss in Q1 2025. Operating income turned positive at $3,881 thousand from a $59,004 thousand loss, though R&D expenses rose 42% YoY to $35,047 thousand and SG&A increased 8% to $38,309 thousand. However, cash and equivalents fell 24% QoQ to $125,391 thousand from $164,086 thousand amid investing outflows.
- ·Operating cash flow turned positive at $5,069 thousand in Q1 2026 versus $42,627 thousand used in Q1 2025.
- ·Marketable securities increased to $408,338 thousand as of March 31 2026 from $365,125 thousand at December 31 2025.
- ·Warrant liability settled to $0 from $2,865 thousand QoQ.
04-05-2026
Biodesix Inc (BDSX) reported Q1 2026 revenue of $25,555, up 42% YoY from $17,958, driven by growth, while narrowing net loss to $7,793 from $11,101 and improving loss from operations to $6,201 from $9,136. However, total operating expenses rose 17% YoY to $31,756, primarily due to higher sales, marketing, G&A at $24,261 (up 19%), and operating cash use increased to $10,168 from $8,602. Cash and equivalents grew to $25,572 from $18,987 at Dec 31, 2025, supported by $16,897 in financing activities including equity issuance, turning stockholders' equity positive at $9,132 from a $2,465 deficit.
- ·Accounts receivable increased to $9,500 from $9,036 QoQ.
- ·Long-term notes payable decreased to $46,487 from $47,445 QoQ.
- ·Weighted-average shares outstanding increased to 9,656 from 7,300 YoY.
- ·Issuance of common stock net proceeds: $16,669 in Q1 2026.
- ·Share-based compensation expense: $1,115 in Q1 2026 vs $972 in Q1 2025.
04-05-2026
Aimei Health Technology Co., Ltd., a SPAC, reported net income of $1,059,768 for the year ended December 31, 2025, down 58.5% YoY from $2,552,215, driven by lower interest income of $1,895,527 (down 47.6% YoY) despite reduced operating losses to $(835,759) from $(1,064,786). The trust account balance shrank to $12,100,110 from $73,784,549 due to redemptions reducing redeemable shares from 6,900,000 to 1,040,332, while liabilities rose to $4,061,660 from $1,506,994 and shareholders' deficit worsened to $(4,058,731). Cash on hand fell sharply to $2,929 from $28,208.
- ·Basic and diluted net income per ordinary share subject to possible redemption: $0.17 (2025) vs. $0.28 (2024).
- ·Accrued expenses increased to $447,997 from $299,514.
- ·Due to a related company rose to $899,601 from $289,780.
- ·Deferred underwriter fee payable steady at $690,000.
- ·Accumulated deficit worsened to $(4,058,944) from $(1,476,823).
04-05-2026
Dorman Products reported Q1 2026 net sales of $528,770 thousand, up 4% YoY from $507,692 thousand, with Heavy Duty segment growing 12% to $57,813 thousand and Light Duty up 4% to $423,739 thousand, while Specialty Vehicle remained flat at $47,218 thousand. However, gross profit fell 8% to $190,155 thousand due to higher cost of goods sold, operating income declined 27% to $58,783 thousand amid elevated SG&A expenses, and net income dropped 24% to $43,551 thousand. Total assets decreased to $2,435,131 thousand QoQ from $2,493,078 thousand, with cash flows from operations down to $43,759 thousand from $51,237 thousand YoY.
- ·Cash and cash equivalents decreased to $43,056 thousand from $49,436 thousand QoQ.
- ·Inventories reduced to $902,422 thousand from $959,019 thousand QoQ.
- ·Revolving credit facility drawn $15,000 thousand in Q1 2026.
- ·Sales of accounts receivable $305,147 thousand in Q1 2026, down from $334,170 thousand YoY.
- ·Weighted average diluted shares 30,423 thousand in Q1 2026 vs 30,810 thousand in Q1 2025.
04-05-2026
For Q1 2026, L.B. Foster reported net sales of $121.1M, up 24% YoY from $97.8M, with gross profit rising 28% to $25.7M and operating income turning positive at $2.0M versus a $1.9M loss in Q1 2025. Net income attributable to the company was $1.5M, compared to a $2.1M loss last year. However, net cash used in operating activities remained negative at $10.4M (improved from $26.1M YoY), cash balances declined QoQ to $4.0M, inventories increased to $68.5M, and long-term debt rose to $59.5M from $42.6M at year-end.
- ·Basic EPS $0.15 in Q1 2026 vs $(0.20) in Q1 2025.
- ·Selling and administrative expenses increased to $23.0M from $21.0M YoY.
- ·Total stockholders’ equity decreased slightly QoQ to $174.5M from $176.0M.
- ·Capital expenditures $3.0M in Q1 2026.
04-05-2026
Monolithic Power Systems Inc. reported Q1 2026 revenue of $804,185 thousand, up 26.2% YoY from $637,554 thousand, driven by gross profit growth of 26.0% to $445,065 thousand and operating income surging 42.8% to $241,152 thousand, resulting in net income of $193,226 thousand, a 43.1% YoY increase. However, cash and cash equivalents decreased 3.3% QoQ to $1,062,930 thousand from $1,099,302 thousand, and net cash from operating activities dipped 2.4% YoY to $250,253 thousand from $256,387 thousand. Total assets grew 6.1% QoQ to $4,448,866 thousand.
- ·Dividends declared at $2.00 per share, totaling $99,281 thousand.
- ·Stock-based compensation expense of $41,098 thousand in Q1 2026, down from $52,806 thousand in Q1 2025.
- ·Property and equipment purchases of $70,849 thousand in Q1 2026, up from $40,342 thousand YoY.
- ·Inventories increased 9.7% QoQ to $619,159 thousand.
- ·Basic EPS of $3.94, up from $2.82 YoY.
04-05-2026
BRC Inc. reported Q1 2026 net revenue of $109,227 thousand, up 21.4% YoY from $89,974 thousand, with gross profit rising 11.1% to $36,088 thousand on higher sales volume. Operating income swung to a profit of $1,319 thousand from a $5,432 thousand loss, aided by an 8.3% reduction in operating expenses to $34,769 thousand; however, the company posted a net loss attributable to BRC Inc. of $15 thousand versus $2,888 thousand last year, and inventories grew modestly 2.2% QoQ to $50,807 thousand. Cash and equivalents increased 130% QoQ to $9,971 thousand, supported by $6,764 thousand in operating cash flow versus a $4,141 thousand outflow in Q1 2025.
- ·Long-term debt, net: $32,586 thousand as of Mar 31 2026 (down slightly QoQ from $32,313 thousand).
- ·Total debt principal: $38,680 thousand as of Mar 31 2026.
- ·Equity-based compensation expense: $2,734 thousand in Q1 2026.
04-05-2026
Pinterest reported Q1 2026 revenue of $1,007,514 up 17.8% YoY from $854,988, driven by growth in core operations. However, the company swung to a net loss of $73,587 from a $8,922 profit in Q1 2025, with operating loss widening to $80,292 due to higher costs across R&D (+15%), sales & marketing (+25%), and a $47,097 restructuring charge. Cash and equivalents dropped sharply to $378,077 from $969,342 QoQ amid $1.98B share repurchases, offset partially by $985M convertible notes issuance and a $447M business acquisition.
- ·Restructuring expenses: $47,097 in Q1 2026 (none in Q1 2025).
- ·Convertible notes, net: $980,169 added to liabilities as of Mar 31 2026.
- ·Share repurchases for tax withholdings: $68,899 in Q1 2026.
- ·Goodwill increased to $475,290 from $100,227 QoQ, likely tied to acquisition.
04-05-2026
U.S. Bancorp reported Q1 2026 net income attributable to the company of $1,945 million, up 13.8% YoY from $1,709 million, driven by 4.7% total net revenue growth to $7,288 million and net interest income up 4.2% to $4,263 million. However, provision for credit losses increased 7.3% to $576 million, noninterest expense rose 0.8% to $4,265 million, and segments showed mixed results with Wealth/Commercial up 19.0% but Payment Services flat at -0.4% and Treasury/Corporate posting wider losses. EPS rose 14.6% to $1.18, while return on tangible common equity dipped slightly to 17.0% from 17.5%.
- ·Nonperforming assets declined 3.9% QoQ to $1,528 million.
- ·Capital ratios stable: CET1 10.8%, Total risk-based capital 14.2%.
- ·Net charge-offs as % of average loans improved to 0.56% from 0.59%.
- ·Treasury and Corporate Support segment net loss widened to $336 million from $325 million YoY.
04-05-2026
Centerspace reported Q1 2026 revenue of $65,069 thousand, down 3.0% YoY from $67,093 thousand, while net loss widened to $14,973 thousand from $4,181 thousand, driven by a $9,700 thousand impairment of real estate investments and higher general/admin expenses. Operating income swung to a $5,393 thousand loss from a $4,746 thousand profit YoY, though operating cash flow remained positive at $21,423 thousand, down 15.8% from $25,429 thousand. Total assets decreased to $1,887,586 thousand QoQ from $1,926,167 thousand, with shareholders' equity falling to $694,968 thousand from $719,156 thousand.
- ·Property operating expenses decreased to $18,242 thousand from $19,068 thousand YoY.
- ·Real estate taxes declined to $7,332 thousand from $7,663 thousand YoY.
- ·Interest expense increased to $10,470 thousand from $9,635 thousand YoY.
- ·Distributions to common shares and units: $12,926 thousand in Q1 2026.
- ·Cash paid for interest: $9,532 thousand in Q1 2026.
04-05-2026
Enzon Pharmaceuticals reported Q1 2026 net sales of $86,537, down 8.2% YoY from $94,188, with gross margin declining sharply 37.5% to $9,000 from $14,406 due to higher cost of sales. However, the net loss narrowed to $6,689 attributable to Viskase (from $13,585 YoY) amid no asset impairment charge this period and improved operating loss of $4,333 versus $14,401; cash rose to $28,619 from $9,217 QoQ, boosted by $40,855 from reverse recapitalization and equity issuance. The company completed Series C Preferred Stock exchanges for common stock on March 25, 2026, issuing 5,658,396 shares to IEH Parties, significantly increasing shares outstanding to 14,331,620 from 6,612,099 QoQ.
- ·Operating cash flow used $16,315 in Q1 2026 versus provided $129 in Q1 2025.
- ·Capital expenditures $8,985 in Q1 2026 versus $7,351 in Q1 2025.
- ·Series C Preferred Stock outstanding: 384 shares at March 31, 2026 (liquidation value $1,129 per share).
04-05-2026
Apple Hospitality REIT reported Q1 2026 total revenue of $337.7M, up 3.1% YoY from $327.7M, driven by growth in room (2.6%), food & beverage (5.1%), and other revenues (9.5%), with Adjusted Hotel EBITDA rising 3.0% to $108.5M. However, operating income declined 5.6% to $48.0M and net income fell 11.3% to $27.7M due to higher hotel operating expenses (up 3.5%), depreciation (up 3.3%), and the absence of a $3.6M gain on real estate sale from prior year. Shareholders' equity decreased to $3.13B from $3.15B at year-end, amid higher capital improvements of $35.8M (up 31.1% YoY).
- ·Debt increased to $1,565.7M from $1,538.6M at December 31, 2025.
- ·Net cash provided by operating activities slightly declined to $48.9M from $49.1M YoY.
- ·Distributions declared at $0.24 per share, totaling $56.7M in Q1 2026.
- ·No gain on sale of real estate in Q1 2026 vs. $3.6M in Q1 2025.
04-05-2026
Cantor Equity Partners I, Inc. (CEPO) reported a net loss of $4,162,576 for the three months ended March 31, 2026, compared to net income of $993,400 in the prior year period, driven by a $5,706,390 unfavorable change in fair value of forward sale securities despite higher interest income of $1,860,667 (up from $1,185,948 YoY). The Trust Account balance grew modestly QoQ to $209,374,148 from $207,513,481, reflecting interest accretion, but total liabilities increased to $20,037,522 from $13,997,210, primarily due to the forward sale liability rising 43% to $18,903,254, and shareholders' deficit widened to $22,805,221 from $16,781,978. Operating losses also worsened to $316,853 from $192,548 YoY amid higher G&A expenses.
- ·Cash remained flat at $25,000 QoQ.
- ·Note payable to related party increased to $769,533 from $485,504 QoQ.
- ·Prepaid expenses increased to $207,301 from $186,718 QoQ.
- ·Basic and diluted EPS for Class A and B shares: $(0.16) in Q1 2026 vs $0.04 in Q1 2025.
- ·No net cash provided by operating, investing, or financing activities in Q1 2026.
04-05-2026
Cantor Equity Partners III, Inc. reported net income of $161,652 for the three months ended March 31, 2026, versus a $26,459 net loss in the same period of 2025, primarily due to $2,485,703 in interest income from the Trust Account. However, the operating loss widened significantly to $2,324,051 from $26,459, driven by elevated general and administrative costs of $2,294,051, while shareholders' deficit deteriorated to $8,281,507 from $5,957,456 at December 31, 2025 amid accretion of redeemable shares.
- ·Cash remained flat at $25,000 as of March 31, 2026 and December 31, 2025.
- ·Accrued expenses increased to $3,729,883 from $1,746,159 QoQ.
- ·Note payable to related party rose to $504,611 from $311,783 QoQ.
- ·Net cash from operating and financing activities both $0 for Q1 2026.
04-05-2026
GeneDx Holdings Corp. reported Q1 2026 total revenue of $102,254, up 17% YoY from $87,115, driven by 18% growth in diagnostic test revenue to $101,299. However, net loss widened dramatically to $63,316 from $6,529 due to a $31,287 impairment loss, higher R&D expenses of $19,804 (up 57%), and SG&A of $74,591 (up 48%), resulting in an operating loss of $57,471. Cash used in operations was $32,408, compared to $10,182 provided in Q1 2025, with total cash declining to $93,924 from $104,997 QoQ.
- ·Goodwill decreased to $1,641 from $13,520 QoQ, likely related to impairment.
- ·Long-term debt increased to $96,732 from $48,176 QoQ, with $96,998 proceeds from new debt and $54,000 repayment to Perceptive.
- ·Payor group A revenue mix increased to 26% YoY from 24%; Payor group B slightly declined to 31% from 32%.
- ·Institutional customers diagnostic revenue declined to $15,528 from $17,604 YoY.
04-05-2026
ADC Therapeutics SA reported Q1 2026 product revenues of $20.0M, up 15% YoY from $17.4M, and narrowed its net loss to $33.0M from $38.6M YoY (-15% improvement), with cash burn from operations halving to $29.7M. However, total revenue declined 9% YoY to $20.9M due to an 86% drop in license revenues to $0.8M, cash and equivalents fell 12% QoQ to $231M, and shareholders' deficit widened to $(216.4M) from $(185.8M). Operating expenses decreased 11% YoY but remain elevated amid ongoing losses.
- ·R&D expenses declined 31% YoY to $19.9M, while selling and marketing rose 20% YoY to $12.7M.
- ·Deferred royalty obligation decreased to $304.7M from $322.5M QoQ.
- ·Inventory, net total $17.1M as of March 31, 2026 (down from $18.5M QoQ), with current portion up to $4.8M.
- ·Accrued R&D costs increased to $23.9M from $18.9M QoQ.
- ·Net cash used in operating activities improved 47% YoY to $29.7M from $56.3M.
04-05-2026
Repay Holdings Corp reported Q1 2026 revenue of $80,794 thousand, up 4.5% YoY from $77,325 thousand, with Consumer Payments revenue increasing 4.3% to $75,068 thousand and Business Payments surging 18.2% to $12,991 thousand. However, net loss attributable to the Company widened 25.1% YoY to $9,940 thousand from $7,947 thousand, loss per Class A share deteriorated to $(0.12) from $(0.09), and cash and cash equivalents fell sharply to $43,770 thousand from $115,692 thousand at December 31, 2025. Total assets decreased to $1,140,803 thousand from $1,199,749 thousand, while long-term debt rose to $390,592 thousand from $280,065 thousand.
- ·Loss from operations nearly flat at $(7) thousand in Q1 2026 vs $(3,620) thousand in Q1 2025.
- ·Stock-based compensation expense $5,020 thousand in Q1 2026 vs $5,344 thousand in Q1 2025.
- ·Capitalized software development costs $11,318 thousand in Q1 2026 vs $10,391 thousand in Q1 2025.
- ·Issuance of long-term debt $110,000 thousand and payments $146,508 thousand in Q1 2026.
04-05-2026
OneWater Marine Inc. reported total revenues of $442.3M for the three months ended March 31, 2026, down 8.5% YoY from $483.5M, driven by a 12.1% decline in new boat sales to $272.0M, though pre-owned boat revenues increased 5.2% to $94.4M; service, parts & other fell 10.7% to $61.9M. For the six months ended March 31, 2026, revenues declined 4.3% YoY to $822.9M, with net loss widening to $20.6M from $14.0M, impacted by $14.0M in restructuring and impairment charges. Balance sheet showed total assets at $1,376M, down from $1,404M at September 30, 2025, with inventories up slightly to $551.4M but stockholders' equity decreasing to $269.4M.
- ·Operating cash flow used $23.8M for six months ended March 31, 2026, worsening from $9.0M used in prior year.
- ·Notes payable – floor plan increased to $473.1M from $419.7M at September 30, 2025.
- ·Stockholders’ equity declined to $269.4M from $285.0M at September 30, 2025.
- ·Proceeds from disposal of a business: $48.7M in investing activities six months ended March 31, 2026.
04-05-2026
ThredUp Inc. reported Q1 2026 revenue of $81,671 thousand, up 14.6% YoY from $71,291 thousand, driven by gross profit growth of 14.7% to $64,660 thousand. However, operating expenses increased 15.3% YoY to $71,249 thousand, leading to a wider operating loss of $6,589 thousand (21.3% increase YoY) and net loss of $6,472 thousand (24.1% increase YoY). Cash provided by operating activities declined 17.2% to $4,754 thousand YoY, while total assets grew 3.1% QoQ to $172,373 thousand as of March 31, 2026.
- ·Current portion of long-term debt reduced to $0 from $3,875 thousand QoQ.
- ·Long-term debt increased to $17,740 thousand from $14,276 thousand QoQ.
- ·Stock-based compensation expense was $5,612 thousand in Q1 2026.
- ·Net cash used in investing activities was $5,015 thousand in Q1 2026, compared to provided by $5,075 thousand YoY.
- ·Shares issued and outstanding increased to 129,004 from 127,027 QoQ due to stock option exercises and RSUs.
04-05-2026
ON Semiconductor reported Q1 2026 revenue of $1,513.3M, up 4.7% YoY from $1,445.7M, with gross profit surging 98.5% to $583.1M due to significantly lower cost of revenue ($930.2M vs $1,151.9M); however, the company still posted an operating loss of $53.4M (improved from $573.7M) and net loss of $33.4M. Segment revenue showed PSG up 14.2% to $736.6M, ISG flat at +0.9% to $236.3M, but AMG down 4.6% to $540.4M; net cash from operations declined 60.3% to $239.1M amid higher inventories and lower payables.
- ·Inventories increased to $2,049.2M from $1,989.6M QoQ.
- ·Restructuring, asset impairments and other charges: $329.3M in Q1 2026 vs $539.3M in Q1 2025.
- ·Non-cash asset impairment charges: $147.0M in Q1 2026.
- ·Weighted-average basic shares outstanding: 394.1M, down from 421.3M YoY.
- ·Treasury stock at cost increased to $(6,433.9)M from $(6,057.9)M.
04-05-2026
Aviat Networks reported Q3 FY2026 total revenues of $100,003 thousand, down 11.2% YoY from $112,640 thousand, with product sales declining 11.0% to $68,405 thousand and services down 11.8% to $31,598 thousand, leading to a net loss of $2,065 thousand versus $3,528 thousand profit last year and operating income dropping 89.9% to $939 thousand. For the nine months ended March 27, 2026, revenues were nearly flat at $318,795 thousand (down 0.1% YoY from $319,266 thousand), but gross profit rose 1.1% to $101,047 thousand and operating income surged 690.7% to $13,415 thousand, driving net income of $3,815 thousand from a $3,856 thousand loss. Cash and equivalents increased 30.8% to $78,129 thousand from $59,690 thousand at fiscal year-end, with operating cash flow turning positive at $10,472 thousand.
- ·Total assets decreased to $616,545 thousand from $633,296 thousand at June 27, 2025.
- ·Total liabilities declined to $344,769 thousand from $370,113 thousand at June 27, 2025.
- ·Stockholders’ equity rose to $271,776 thousand from $263,183 thousand at June 27, 2025.
- ·Net cash provided by operating activities for 9M FY2026: $10,472 thousand vs used $4,790 thousand prior year.
- ·Accounts receivable increased to $187,624 thousand from $180,321 thousand at June 27, 2025.
04-05-2026
RB Global Inc. reported Q1 2026 total revenue of $1,234.6 million, up 11% YoY from $1,108.6 million, driven by 32% growth in inventory sales revenue to $336.9 million and 5% increase in service revenue to $897.7 million, while operating income rose 15% to $217.5 million and net income attributable to common stockholders increased 21% to $124.6 million. Operating cash flow strengthened significantly to $224.1 million from $156.8 million YoY. However, comprehensive income declined 4% to $118.9 million due to a $16.7 million foreign currency translation loss, and inventory decreased 15% QoQ to $119.1 million.
- ·Diluted EPS available to common stockholders $0.66 in Q1 2026, up from $0.55 YoY.
- ·Cash and cash equivalents increased to $667.2 million from $531.5 million QoQ.
- ·Total assets grew to $12,397.2 million from $12,143.0 million at Dec 31, 2025.
- ·Acquisition of VeriTread non-controlling interests for $14.2 million in cash.
- ·Net cash used in investing activities improved to $78.8 million from $101.9 million YoY.
04-05-2026
Advanced Energy Industries Inc reported strong Q1 2026 results with revenue of $511.0M, up 26.3% YoY from $404.6M, gross profit of $200.9M (+33.5% YoY), operating income of $68.3M (+123.2% YoY), and net income of $66.8M (+170.4% YoY). Diluted EPS rose to $1.58 from $0.65 YoY. However, cash from operating activities swung to negative $6.0M from +$28.9M YoY due to working capital changes including $52.4M increase in accounts receivable and $48.4M in inventories, resulting in cash declining $89.8M QoQ to $699.5M.
- ·Property and equipment purchases (capex) increased to $36.6M from $13.9M YoY.
- ·Stock-based compensation expense rose to $18.1M from $13.0M YoY.
- ·Dividends declared $0.10 per share, total payments $3.8M in both periods.
- ·Intangible assets net decreased to $112.4M from $117.7M QoQ.
04-05-2026
Merck & Co., Inc. reported Q1 2026 sales of $16,286 million, up 4.9% YoY from $15,529 million, with alliance revenues rising 41% to $502 million driven by Koselugo (+266%) and Lynparza (+9%), while Lenvima remained flat. However, a $8,540 million research and development asset acquisition charge contributed to a net loss of $4,240 million versus a $5,079 million profit in Q1 2025, alongside sharply higher R&D expenses of $12,592 million (up 248% YoY). Cash from operations improved 57% to $3,918 million, but cash and equivalents fell to $5,327 million from $14,565 million at year-end, reflecting an $8,779 million acquisition of Cidara Therapeutics.
- ·Total current assets declined to $35,015 million from $43,516 million at Dec 31, 2025.
- ·Adempas/Verquvo total sales increased 7.1% YoY to $196 million.
- ·Treasury stock increased to 1,107,410,143 shares from 1,102,476,756 shares at Dec 31, 2025.
04-05-2026
Vitesse Energy reported Q1 2026 total revenue of $67.4 million, up 1.9% YoY from $66.2 million, driven by slight increases in oil (+1.9%) and natural gas (+2.0%) revenues, with operating income rising 10% to $5.9 million. However, a massive $55.0 million net commodity derivative loss led to a net loss of $42.3 million (EPS -$1.05), compared to net income of $2.7 million (EPS $0.08) in Q1 2025, while operating cash flow improved to $24.0 million from $17.5 million. Equity declined to $570.4 million from $629.3 million at year-end 2025 amid the loss and $17.8 million in dividends.
- ·Unrealized loss on commodity derivatives $48.2 million in Q1 2026 cash flow adjustments.
- ·Revolving credit facility increased to $144.5 million from $124.5 million at Dec 31 2025.
- ·Common stock dividends declared at $0.4375 per share Q1 2026 (down from $0.5625 in Q1 2025).
- ·WTI hedges for Q2 2026: 613,509 Bbls at weighted average $66.77.
04-05-2026
For the three months ended March 31, 2026, Gaia, Inc. reported net revenues of $24,313 thousand, up 2% YoY from $23,840 thousand, with international revenues increasing 10% to $10,555 thousand while U.S. revenues declined 3% to $13,758 thousand. Gross profit remained flat at $20,906 thousand YoY, but operating expenses rose 2% leading to a wider operating loss of $1,428 thousand versus $1,014 thousand, and net loss attributable to common shareholders increased to $1,255 thousand from $1,014 thousand. Cash provided by operating activities improved 15% to $1,493 thousand, though total equity dipped slightly to $101,006 thousand from $102,130 thousand at year-end.
- ·Cash and cash equivalents decreased to $13,098 thousand as of March 31, 2026 from $13,540 thousand at December 31, 2025.
- ·Deferred revenue increased to $20,539 thousand as of March 31, 2026 from $18,502 thousand at December 31, 2025.
- ·Net cash used in investing activities was $1,854 thousand in Q1 2026, primarily due to additions to property and equipment.
04-05-2026
Twist Bioscience reported revenues of $110,715 thousand for the three months ended March 31, 2026, up 19.3% YoY from $92,793 thousand, and $214,413 thousand for the six months ended March 31, 2026, up 18.1% YoY from $181,506 thousand. However, net loss widened to $44,021 thousand in the quarter (from $39,328 thousand YoY) and $74,528 thousand in the six months (from $70,922 thousand YoY), driven by higher SG&A expenses to $76,085 thousand and $7,205 thousand in litigation settlement costs. Cash and cash equivalents declined to $122,670 thousand as of March 31, 2026, from $183,049 thousand at September 30, 2025, with net cash used in operating activities increasing to $42,373 thousand for the six months from $34,414 thousand YoY.
- ·Selling, general and administrative expenses increased to $76,085 thousand for three months ended March 31, 2026 from $63,671 thousand YoY.
- ·Litigation settlement costs of $7,205 thousand recorded in three months ended March 31, 2026.
- ·Stock-based compensation expense of $32,238 thousand for six months ended March 31, 2026.
- ·Total stockholders’ equity decreased to $455,094 thousand as of March 31, 2026 from $472,958 thousand at September 30, 2025.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 50 filings
More from: US Earnings Financial Results SEC Filings
🇺🇸 More from United States
View all →April 27, 2026
US Pre-Market SEC Filings Roundup — April 27, 2026
US Pre-Market SEC Filings Roundup
April 27, 2026
US Merger & Acquisition SEC Filings — April 27, 2026
US Merger & Acquisition SEC Filings
April 27, 2026
US Corporate Board Director Changes SEC Filings — April 27, 2026
US Corporate Board Director Changes SEC Filings
April 27, 2026
US Executive Officer Management Changes SEC — April 27, 2026
US Executive Officer Management Changes SEC